Cellectar Biosciences Long Term Debt

Cellectar Biosciences (CLRB) currently reports a long-term debt of $1.5M as of March 2026. That compares with $390K in the prior-year period — up 295.9% year over year. Use the charts on this page to explore Cellectar Biosciences's long-term debt history and peer comparisons.

Cellectar Biosciences's long-term debt increased from $390K to $1.5M — a 295.9% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Cellectar Biosciences reported $1.5M in long-term debt as of March 2026. That compares with $390K in the prior-year period — up 295.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $1.5M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Cellectar Biosciences, and consider following CLRB for alerts when major investors trade the stock.

Cellectar Biosciences is classified in the Healthcare sector. On long-term debt, it currently shows $1.5M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CLRB with unrelated industries.